Seek Returns logo

NTRA vs. TWST: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at NTRA and TWST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolNTRATWST
Company NameNatera, Inc.Twist Bioscience Corporation
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyBiotechnology
Market Capitalization22.30 billion USD1.65 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJuly 1, 2015October 31, 2018
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of NTRA and TWST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NTRA vs. TWST: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolNTRATWST
5-Day Price Return1.47%-0.69%
13-Week Price Return6.55%-2.73%
26-Week Price Return-5.87%-42.91%
52-Week Price Return32.51%-35.49%
Month-to-Date Return21.55%-18.41%
Year-to-Date Return2.63%-41.06%
10-Day Avg. Volume1.20M1.80M
3-Month Avg. Volume1.34M1.28M
3-Month Volatility36.39%59.04%
Beta1.772.38

Profitability

Return on Equity (TTM)

NTRA

-22.21%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

NTRA has a negative Return on Equity of -22.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

TWST

-18.45%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

TWST has a negative Return on Equity of -18.45%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

NTRA vs. TWST: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

NTRA

-12.89%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

NTRA has a negative Net Profit Margin of -12.89%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

TWST

-23.51%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

TWST has a negative Net Profit Margin of -23.51%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

NTRA vs. TWST: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

NTRA

-14.95%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

NTRA has a negative Operating Profit Margin of -14.95%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

TWST

-39.30%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

TWST has a negative Operating Profit Margin of -39.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

NTRA vs. TWST: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

SymbolNTRATWST
Return on Equity (TTM)-22.21%-18.45%
Return on Assets (TTM)-15.03%-13.84%
Net Profit Margin (TTM)-12.89%-23.51%
Operating Profit Margin (TTM)-14.95%-39.30%
Gross Profit Margin (TTM)62.86%49.24%

Financial Strength

Current Ratio (MRQ)

NTRA

3.72

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

NTRA’s Current Ratio of 3.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

TWST

3.90

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

TWST’s Current Ratio of 3.90 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

NTRA vs. TWST: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

NTRA

0.06

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

NTRA’s Debt-to-Equity Ratio of 0.06 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

TWST

0.00

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

TWST’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NTRA vs. TWST: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

NTRA

-57.80

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

NTRA has a negative Interest Coverage Ratio of -57.80. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

TWST

-235.67

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

TWST has a negative Interest Coverage Ratio of -235.67. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

NTRA vs. TWST: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

SymbolNTRATWST
Current Ratio (MRQ)3.723.90
Quick Ratio (MRQ)3.443.45
Debt-to-Equity Ratio (MRQ)0.060.00
Interest Coverage Ratio (TTM)-57.80-235.67

Growth

Revenue Growth

NTRA vs. TWST: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NTRA vs. TWST: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NTRA

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NTRA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

TWST

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TWST currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NTRA vs. TWST: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

NTRA

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NTRA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

TWST

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TWST has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NTRA vs. TWST: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

SymbolNTRATWST
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

NTRA

--

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

P/E Ratio data for NTRA is currently unavailable.

TWST

--

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

P/E Ratio data for TWST is currently unavailable.

NTRA vs. TWST: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

NTRA

11.15

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

NTRA’s P/S Ratio of 11.15 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

TWST

4.39

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

In the lower quartile for the Biotechnology industry, TWST’s P/S Ratio of 4.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

NTRA vs. TWST: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

NTRA

18.51

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

NTRA’s P/B Ratio of 18.51 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

TWST

4.61

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

TWST’s P/B Ratio of 4.61 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

NTRA vs. TWST: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

SymbolNTRATWST
Price-to-Earnings Ratio (TTM)----
Price-to-Sales Ratio (TTM)11.154.39
Price-to-Book Ratio (MRQ)18.514.61
Price-to-Free Cash Flow Ratio (TTM)209.51--